Thibault De La Motte Rouge

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.8K citations

Brca1/2 Mutation, Medicine, Cancer Management +10

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andrés Poveda, Anne Floquet, Jonathan A. Ledermann et al. · The Lancet Oncology · 2021 · 391 citations · Full text

Clinical Response of Carcinomas Harboring the BRD4–NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628

Anastasios Stathis, Emanuele Zucca, Mohamed Békradda et al. · Cancer Discovery · 2016 · 371 citations · Full text

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

François‐Clément Bidard, Anne‐Claire Hardy‐Bessard, Florence Dalenc et al. · The Lancet Oncology · 2022 · 285 citations

Breast Oncology, Esr1 Mutation, Endocrine-related Cancer +10

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies

Nader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès et al. · European Urology · 2014 · 164 citations

Medicine, Hormonal Receptor, Patients Progressing +6